|The MCP-4 ccl13 (Catalog #MBS690546) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Mouse Anti-Human MCP-4 reacts with Human and may cross-react with other species as described in the data sheet.
Western Blot: In combination with appropriate secondary detection antibodies this antibody can be used in concentrations of 20-40 ng/ml. Researchers should empirically determine the suitability of the MCP-4 ccl13 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The MCP-4 ccl13 product has the following accession number(s) (GI #4885587) (NCBI Accession #NP_005399.1) (Uniprot Accession #Q99616). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Monocyte Chemoattractant Protein-4 (MCP-4), is a CC chemokine that acts as a chemoattractant for monocytes, eosinophils and T cells and as an activator of basophils. Human MCP-4/CCL13 cDNA encodes a 98 amino acid residue precursor protein with a 23 amino acid residue hydrophobic signal peptide that is cleaved to yield an 8 kDa, 75 aa mature CCL13. Mature MCP-4 lacks any potential N-glycosylation sites and shares a pyroglutamate proline motif with other human MCP proteins. Human MCP-4 is most homologous to MCP-1, -3 and Eotaxin, exhibiting approximately 65-66% amino acid sequence identity. CCL13 or MCP-4 mRNA is expressed by a number of activated cell types, including endothelial cells, macrophages, bronchial epithelium and type II alveolar cells, and perhaps lymphocytes. The bioactivities of MCP-4 are mediated by the CC chemokine receptors CCR2 and CCR3.
Antibody Generation: Monoclonal antibodies were produced in BALB/c mice using recombinant human MCP-4 as the immunizing antigen. This IgG1, antibody was purified from a Protein A chromatography column. Buffer: none
Neutralization: To yield one-half maximal inhibition [ND50] of the biological activity of hMCP-4 (100 ng/ml), a concentration of 1-5 ug/ml of this antibody is required. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing MCP-4 are readily searchable from our website. Different antibodies against the same target such as MCP-4 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results. Adenocarcinoma, Carcinoma, Hematologic Diseases, Hodgkin Disease, Inflammation, Kidney Diseases, Liver Diseases, Liver Neoplasms, Muscular Diseases, Neoplasms, Experimental are some of the diseases may be linked to Mouse Anti-Human MCP-4. The following patways have been known to be associated with this gene.